RU2660706C1 - Скрининг-тест определения контактного пути коагуляции (СТОКПК) - Google Patents
Скрининг-тест определения контактного пути коагуляции (СТОКПК) Download PDFInfo
- Publication number
- RU2660706C1 RU2660706C1 RU2017133476A RU2017133476A RU2660706C1 RU 2660706 C1 RU2660706 C1 RU 2660706C1 RU 2017133476 A RU2017133476 A RU 2017133476A RU 2017133476 A RU2017133476 A RU 2017133476A RU 2660706 C1 RU2660706 C1 RU 2660706C1
- Authority
- RU
- Russia
- Prior art keywords
- coagulation
- plasma
- test
- samples
- hemostasis
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 79
- 230000015271 coagulation Effects 0.000 title claims abstract description 50
- 238000005345 coagulation Methods 0.000 title claims abstract description 50
- 210000002381 plasma Anatomy 0.000 claims abstract description 67
- 230000037361 pathway Effects 0.000 claims abstract description 27
- 230000003027 hypercoagulation Effects 0.000 claims abstract description 22
- 206010020608 Hypercoagulation Diseases 0.000 claims abstract description 21
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 14
- 238000005259 measurement Methods 0.000 claims abstract description 11
- 239000001110 calcium chloride Substances 0.000 claims abstract description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 8
- 239000012190 activator Substances 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 12
- 230000000023 hypocoagulative effect Effects 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 abstract description 35
- 238000000034 method Methods 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000011534 incubation Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000006978 adaptation Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 230000004913 activation Effects 0.000 description 18
- 238000001994 activation Methods 0.000 description 18
- 108090000190 Thrombin Proteins 0.000 description 16
- 229960004072 thrombin Drugs 0.000 description 16
- 101710162629 Trypsin inhibitor Proteins 0.000 description 8
- 229940122618 Trypsin inhibitor Drugs 0.000 description 8
- 239000002753 trypsin inhibitor Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 7
- 102000008946 Fibrinogen Human genes 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 108010094028 Prothrombin Proteins 0.000 description 7
- 102100027378 Prothrombin Human genes 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 229940012952 fibrinogen Drugs 0.000 description 7
- 229940039716 prothrombin Drugs 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000003154 D dimer Substances 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 239000003805 procoagulant Substances 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000013168 hemostasis test Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000678 plasma activation Methods 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017133476A RU2660706C1 (ru) | 2017-09-26 | 2017-09-26 | Скрининг-тест определения контактного пути коагуляции (СТОКПК) |
| PCT/RU2018/000601 WO2019066685A1 (fr) | 2017-09-26 | 2018-09-13 | Test de criblage pour déterminer les voies de contact de coagulation (stokpk) |
| EA201900323A EA037879B1 (ru) | 2017-09-26 | 2018-09-13 | Скрининг-тест определения контактного пути коагуляции (стокпк) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017133476A RU2660706C1 (ru) | 2017-09-26 | 2017-09-26 | Скрининг-тест определения контактного пути коагуляции (СТОКПК) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2660706C1 true RU2660706C1 (ru) | 2018-07-09 |
Family
ID=62816032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017133476A RU2660706C1 (ru) | 2017-09-26 | 2017-09-26 | Скрининг-тест определения контактного пути коагуляции (СТОКПК) |
Country Status (3)
| Country | Link |
|---|---|
| EA (1) | EA037879B1 (fr) |
| RU (1) | RU2660706C1 (fr) |
| WO (1) | WO2019066685A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767891C2 (ru) * | 2020-08-21 | 2022-03-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Северный государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ скринингового обследования для выявления групп риска развития гиперкоагуляционного состояния в условиях экспедиционной работы в Арктике |
| RU2772195C1 (ru) * | 2021-10-27 | 2022-05-18 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) | Способ определения функциональной активности антитромбина iii в плазме крови |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337858B1 (fr) * | 2000-10-27 | 2011-03-16 | Cambridge University Hospitals NHS Foundation Trust | Reactif et kit permettant de determiner la coagulabilite globale et le potentiel hemostatique |
| RU2607658C2 (ru) * | 2011-03-08 | 2017-01-10 | Фиикс Диагностикс | Способ контроля антикоагулянтной терапии |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2556116C2 (ru) * | 2013-11-28 | 2015-07-10 | Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор") | Высокоселективный ингибитор контактной активации на основе инфестина 4 |
-
2017
- 2017-09-26 RU RU2017133476A patent/RU2660706C1/ru active
-
2018
- 2018-09-13 EA EA201900323A patent/EA037879B1/ru not_active IP Right Cessation
- 2018-09-13 WO PCT/RU2018/000601 patent/WO2019066685A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337858B1 (fr) * | 2000-10-27 | 2011-03-16 | Cambridge University Hospitals NHS Foundation Trust | Reactif et kit permettant de determiner la coagulabilite globale et le potentiel hemostatique |
| RU2607658C2 (ru) * | 2011-03-08 | 2017-01-10 | Фиикс Диагностикс | Способ контроля антикоагулянтной терапии |
Non-Patent Citations (3)
| Title |
|---|
| CHANG F-Y. et al. Optical coherence tomography-guided laser microsurgery for blood coagulation with continuous-wave laser diode // Scientific Reports, 2015, V.5, pp.1-9. * |
| АТАУЛЛАХАНОВА Ф.И. и др. Пространственные аспекты динамики свертывания крови. II. Феноменологическая модель // Биофизика, 1994, Т.39, стр.97-106. * |
| АТАУЛЛАХАНОВА Ф.И. и др. Пространственные аспекты динамики свертывания крови. II. Феноменологическая модель // Биофизика, 1994, Т.39, стр.97-106. CHANG F-Y. et al. Optical coherence tomography-guided laser microsurgery for blood coagulation with continuous-wave laser diode // Scientific Reports, 2015, V.5, pp.1-9. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767891C2 (ru) * | 2020-08-21 | 2022-03-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Северный государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ скринингового обследования для выявления групп риска развития гиперкоагуляционного состояния в условиях экспедиционной работы в Арктике |
| RU2772195C1 (ru) * | 2021-10-27 | 2022-05-18 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) | Способ определения функциональной активности антитромбина iii в плазме крови |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019066685A1 (fr) | 2019-04-04 |
| EA201900323A1 (ru) | 2019-11-29 |
| EA037879B1 (ru) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10954549B2 (en) | Detection and classification of an anticoagulant using a clotting assay | |
| Ray et al. | Relationship of platelet aggregation to bleeding after cardiopulmonary bypass | |
| US6245573B1 (en) | Rapid assessment of the coagulant activity of blood | |
| JP3143694B2 (ja) | 血小板活性の測定 | |
| US20030064414A1 (en) | Rapid assessment of coagulation activity in whole blood | |
| EP2235542B1 (fr) | Procédé in vitro de diagnostic pour évaluer la maladie de von willebrand et le risque saignement associé avec la maladie de von willebrand et les troubles acquis ou congénitaux de fonction plaquettaire | |
| DE60315151T2 (de) | Diagnostischer test zur bestimmung der konzentration einer transienten proteolytischen aktivität in zusammengesetzten biologischen medien | |
| KR20020042622A (ko) | 전혈내 응고 인자 활성을 측정하는 방법 | |
| Hoffmann et al. | Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. | |
| US7202048B2 (en) | Onset of force development as a marker of thrombin generation | |
| RU2660706C1 (ru) | Скрининг-тест определения контактного пути коагуляции (СТОКПК) | |
| US20170234853A1 (en) | Method for determining the structural profile of a fibrin clot reflecting the stability thereof, in order to predict the risk of bleeding, thrombosis or rethrombosis | |
| WO2014166508A1 (fr) | Procédé pour déterminer l'état fonctionnel d'un système d'hémostase | |
| RU2213976C2 (ru) | Способ оценки агрегационных свойств тромбоцитов | |
| KR20200118428A (ko) | 활성탄을 사용하여 지혈 장애를 진단하는 방법 | |
| Hosokawa et al. | New methodological approaches for assessing thrombus formation in cardiovascular disease | |
| Li et al. | Prothrombin fragment F 1+ 2 and oral anticoagulant therapy | |
| Djabbarova et al. | A SUMMARY OF THE CLINICAL SIGNIFICANCE AND LABORATORY SPECIFICITY OF THE EVALUATION TEST DEFINITIONS | |
| Giddings et al. | Laboratory support in the diagnosis of coagulation disorders | |
| Kato et al. | Differences in the composition of activated partial thromboplastin time (APTT) reagents affect clot waveform analysis | |
| US20220252624A1 (en) | Method for determining the risk of a thromboembolic event | |
| WO2024163247A1 (fr) | Cartouche jetable pour la classification d'anticoagulant et procédé d'utilisation | |
| RU2204141C2 (ru) | Способ определения активности фактора xiii | |
| RU2189590C2 (ru) | Способ определения плазминогена | |
| RU2158931C1 (ru) | Способ прогнозирования нестабильности течения ишемической болезни сердца |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |